Acadia Pharma (ACAD) – FDA
-
Acadia Pharma (ACAD) Announces Trofinetide New Drug Submission for Treatment of Rett Syndrome Has Been Accepted for Filing and Priority Review by Health Canada
-
Acadia Pharma (ACAD) to stop pimavanserin trials after failure
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
Back to ACAD Stock Lookup